Pfizer Initiatives Partnerships
The Pfizer Initiative in International Health at the University of Virginia has many significant partnerships both in the United States and abroad.
In Kampala, Uganda, Pfizer joined with Makerere University, international infectious disease experts, the Ugandan government, and non governmental organizations to design and build the Infectious Diseases Institute (IDI) where infectious disease experts train African doctors in the prevention and treatment of HIV/AIDS. This regional training and treatment center is strengthening local capacity in HIV/AIDS care. The IDI has trained more than 650 healthcare providers from 21 African countries.
Training health care professionals in the latest treatment options is an important component in fighting the HIV/AIDS crisis.
It often takes days for African doctors to receive essential lab results, and too many patients lack access to adequate health care. This will soon change with the building of the Infectious Diseases Institute on the campus of Makerere University in Kampala, Uganda, site of one of the continent's leading medical schools. Along with a global partnership of infectious disease experts, the Academic Alliance for AIDS Care and Prevention and non-governmental organizations such as the San Francisco AIDS Foundation, the Infectious Diseases Society of America and The AIDS Support Organization (TASO) in Uganda, Pfizer is supporting efforts to develop new approaches to address the HIV/AIDS epidemic.
The Institute is expected to have a significant impact in Africa, striking at the core of the AIDS epidemic by providing extensive training to health care providers and advanced treatment methods to patients, including:
- Provision of enhanced HIV care for adults, children and families, including anti-retrovirals and prophylaxis for opportunistic infections;
- Education and training for African physicians and health care providers in HIV care and prevention;
- A state-of-the-art diagnostic laboratory to monitor HIV therapy and to support diagnosis of opportunistic infections, tropical diseases and sexually-transmitted diseases (STDs);
- Clinical research to identify the best approaches for patient care, including directly observed therapy and once-a-day treatment regimens;
- Treatment of thousands of patients annually.